Lucid Diligence Brief: Chiesi to acquire KalVista Pharmaceuticals
Lucid Diligence Brief: Chiesi to acquire KalVista Pharmaceuticals Professional…
Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J
Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J…
Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma
Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in…
Lucid Diligence Brief: Tenaya Therapeutics and Alnylam Cardiovascular Collaboration
Lucid Diligence Brief: Tenaya Therapeutics and Alnylam Cardiovascular…
Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on genetic epilepsies
Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on…
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL
Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL Professional audiences…
Healthcare and Pharma Industry Trends H2 2025: From Innovation to Execution
An in-depth analysis of pharma and healthcare industry trends in H2 2025,…
Lucid Diligence Brief: Angitia Biopharmaceuticals $130 million Series D
Lucid Diligence Brief: Angitia Biopharmaceuticals $130 million Series D…
Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission
Lucid Diligence Brief: Ultragenyx UX111 BLA resubmission Professional audiences…
Lucid Diligence Brief: Mendra $82 million Series A to support AI-enabled rare-disease therapeutics
Lucid Diligence Brief: Mendra $82 million Series A to support AI-enabled…
Lucid Diligence Brief: Aurora Therapeutics launches to scale personalized CRISPR
Lucid Diligence Brief: Aurora Therapeutics launches to scale personalized…
Respiratory Today—January 9, 2026
This respiratory update spotlights reflects strong momentum across respiratory…